Foundayo side effects: what the trials actually showed

If you search "is Foundayo safe", most of what comes back is either marketing gloss or alarm. Neither is much use. What is useful are the numbers from the published phase 3 trials — how often each side effect actually happened, how that compared with placebo, and how many people stopped taking the tablet because of it. This page sets those numbers out, plus the serious risks on the US label and who the medicine is not for.

Where these numbers come from

Foundayo is Eli Lilly's once-daily oral GLP-1 receptor agonist, approved by the US FDA on 1 April 2026 but not yet licensed in the UK. The safety data below comes from ATTAIN-1, a 72-week randomised, double-blind, placebo-controlled trial in 3,127 adults with obesity (or overweight with weight-related conditions, excluding type 2 diabetes), published in the New England Journal of Medicine. A companion trial, ATTAIN-2, tested the tablet in more than 1,600 adults who also had type 2 diabetes; the side-effect frequencies on this page, however, are drawn specifically from ATTAIN-1.

One caution before the table: the trials used research doses labelled 6 mg, 12 mg and 36 mg. The marketed tablet comes in different strengths — 0.8 mg up to 17.2 mg — so the trial dose numbers do not map one-to-one onto the strengths a prescriber would use. The pattern (side effects rise with dose) is what carries over, not the milligram labels. Our Foundayo dosage guide explains the marketed strengths and the step-up schedule in detail.

The common side effects, with trial frequencies

The dominant side effects were gastrointestinal — the same family of effects seen with every GLP-1 medicine. In ATTAIN-1 they were mostly mild to moderate, and more frequent at higher doses:

Two things are worth noticing in that table. First, the placebo column is not zero — around one in ten people reported nausea, constipation or diarrhoea while taking a dummy tablet, so the drug's true added effect is the gap between the columns, not the raw percentage. Second, vomiting shows the clearest dose relationship, roughly doubling from the lowest to the highest research dose.

Beyond the big four, the FDA label lists further common effects whose individual frequencies are not all broken out: indigestion, abdominal pain, headache, abdominal swelling or distension, fatigue, belching, heartburn, gas and hair loss. Hair loss tends to surprise people, but it appears on the label alongside the digestive effects.

How many people stopped taking it

Percentages of people experiencing nausea only tell half the story; what matters just as much is whether the side effects were bad enough to make people quit. In ATTAIN-1, discontinuation because of adverse events was:

• 5.3% at the 6 mg research dose
• 7.9% at 12 mg
• 10.3% at 36 mg
• 2.7% on placebo

Read plainly: even at the highest dose, fewer than one in ten participants stopped specifically because of side effects. That is consistent with the "mostly mild to moderate" description in the published paper, but it is not trivial either — one person in ten stopping over side effects is a real cost, and it is the main reason the dosing is designed the way it is.

Why the dose is increased so slowly

The marketed schedule starts at 0.8 mg once daily and steps up through six strengths to a maximum of 17.2 mg, with at least 30 days at each step. The label's stated rationale is exactly this side-effect profile: gradual escalation reduces the risk of gastrointestinal reactions, and the maintenance dose is chosen on response and tolerability rather than defaulting to the maximum. If nausea at higher doses is the problem, staying longer at a lower step — or settling at a lower maintenance dose — is the standard answer. The full schedule is on our dosage page.

Serious but rare risks

The FDA label carries warnings that apply across the GLP-1 class, plus the standard contraindications. These events are rare, but they are the reason this is a prescription medicine and not a supplement:

• Thyroid C-cell tumours. The label warns the medicine may cause thyroid tumours, including medullary thyroid carcinoma (MTC). This is the class warning, based on rodent findings.
• Acute pancreatitis. Sudden, severe inflammation of the pancreas.
• Severe gastrointestinal reactions. Beyond ordinary nausea — reactions severe enough to need medical attention.
• Acute kidney injury. Usually secondary to dehydration from prolonged vomiting or diarrhoea, which is why persistent GI symptoms should not simply be endured.
• Gallbladder disease. A recognised effect across GLP-1 medicines, particularly with rapid weight loss.
• Hypoglycaemia. Mainly a risk when combined with insulin or sulfonylureas in people with diabetes.
• Diabetic retinopathy and mood. The label includes class-level precautions on monitoring diabetic retinopathy and on watching for suicidal ideation, as with other weight-management medicines.

Who it is not for

The label rules the medicine out entirely for two groups:

• People with a personal or family history of medullary thyroid carcinoma (MTC).
• People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Beyond the outright contraindications, the warnings above mean a prescriber would weigh the medicine carefully for anyone with a history of pancreatitis, gallbladder disease, kidney problems, or diabetes treated with insulin or a sulfonylurea. This is precisely the sort of judgement a website cannot make for you.

How this compares with injectable GLP-1s

At a high level, the tablet's safety profile looks like the class it belongs to. The gastrointestinal effects — nausea, constipation, diarrhoea, vomiting, easing with slow titration — are the same ones reported for the injectable GLP-1 medicines already used in the UK, and the ATTAIN-2 trial reported cardiometabolic changes consistent with the injectable GLP-1s. This page does not rank Foundayo against any specific injectable for tolerability: the frequencies above come from Foundayo's own trials, not from a direct comparison, so treat "better or worse tolerated" claims with caution. What can be said is that being a small-molecule tablet rather than an injected peptide changes how you take it — any time of day, no food or water restrictions — not the fundamental character of its side effects.

The UK situation, and reporting side effects

As of mid-2026 Foundayo has no MHRA licence. Lilly has submitted it for approval in more than 40 countries including the UK, and the industry expectation is a decision in late 2026 to early 2027 — but that is an expectation, not a commitment from Lilly or the MHRA. Until a licence exists, it is not licensed for general supply in the UK, and anything sold as "Foundayo" to UK buyers today is being sold outside the law and is potentially dangerous. Our UK availability page tracks the regulatory position.

If you experience a suspected side effect from any medicine — licensed or not — report it through the MHRA Yellow Card scheme. Yellow Card reports are how the UK regulator spots safety signals that trials are too small or too short to catch, and reports about products bought from illegal sellers are especially valuable.

When to seek help

General guidance for anyone taking a GLP-1 medicine, drawn from the risks on the label:

• Severe, persistent abdominal pain, with or without vomiting — possible pancreatitis or gallbladder disease. Seek urgent medical advice.
• Vomiting or diarrhoea you cannot keep under control — dehydration can injure the kidneys. Contact a clinician rather than waiting it out.
• A lump or swelling in the neck, hoarseness, or trouble swallowing — symptoms the thyroid warning tells patients to report.
• Signs of low blood sugar (shakiness, sweating, confusion) if you also use insulin or a sulfonylurea.
• Low mood or thoughts of self-harm — speak to your GP promptly; this is a monitored precaution for weight-management medicines.

None of this replaces the advice of your GP or pharmacist, who can see your history and the label in force at the time.

Common questions